

ORIGINAL ARTICLE

Pregnancy Outcomes in Association with STDs including genital HSV-2 shedding in a South African Cohort Study

Dhayendre Moodley,¹ Benn Sartorius,² Savithree Madurai,³ Vani Chetty,¹ Suzanne Maman⁴

¹Department of Obstetrics and Gynaecology, University of KwaZulu-Natal, Durban, South Africa

²Discipline of Public Health Medicine, School of Nursing and Public Health, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

³Global Clinical Virology Laboratory, Durban, South Africa

⁴Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Correspondence to

Dr Dhayendre Moodley, Department of Obstetrics and Gynaecology, University of KwaZulu-Natal, Durban, South Africa 4013; moodleyd1@ukzn.ac.za

Received 19 January 2017

Revised 2 March 2017

Accepted 14 March 2017

Published Online First

10 April 2017

ABSTRACT

Objectives Genital herpes simplex virus-2 (HSV-2) shedding in pregnant women in association with neonatal herpes infection has been widely studied but there is limited evidence of its association with pregnancy outcomes.

Methods In this retrospective observational study, we included a subgroup of pregnant women who were enrolled in a randomized control behavioural intervention study that was conducted in South Africa in 2008–2010. In pregnancy, women had a HIV rapid test done and a genital swab taken to test for curable STIs and HSV-2 DNA. Subsequent visits were scheduled for 6, 10, 14 weeks and 9 months post-delivery. Pregnancy outcomes were documented at the 6-week or 10-week postpartum visit. Women were treated syndromically for curable STIs.

Results Among 615 women included in this data analysis, 36.6% (n=225) tested HIV positive and 8.3% (n=51) tested positive for genital HSV-2 shedding during pregnancy. Women <24 years and HIV-1 seropositive women were 1.5 and 2.5 times more likely to test positive for HSV-2 genital shedding respectively. STI treatment records were available for 158/205 (77.1%) women; all 87 women with symptomatic STIs were treated the same day, and 50/71 (70.4%) asymptomatic women received treatment at the subsequent visit. Remaining 21 (29.6%) asymptomatic women did not receive treatment because they failed to return for antenatal follow-up. In a multivariable regression analysis, genital HSV-2 shedding, HIV-1, *Neisseria gonorrhoea*, *Chlamydia trachomatis* and *Trichomonas vaginalis* were not associated with preterm deliveries, still births and low birth weight. However with stratification by treatment for a STI, asymptomatic women who were not treated were 3.3 times more likely to deliver prematurely (33.3%; n=6/18) when compared to women who were treated during pregnancy (13.2%; n=15/114) (p=0.042).

Conclusions Genital HSV-2 shedding in pregnancy does not appear to alter pregnancy outcomes. Untreated curable STIs (*T.vaginalis*, *C.trachomatis*, *N.gonorrhoea*) were more likely associated with preterm births.

INTRODUCTION

Worldwide, women in their reproductive age bear the brunt of the HIV-1 epidemic, and women aged 14–24 years are at particularly high risk.¹ Younger women are also disproportionately vulnerable to

other STIs, unplanned pregnancies and adverse perinatal outcomes.^{2–4} In a secondary analysis of a South African cohort study, the prevalence of *Neisseria gonorrhoeae* (8.6%), *Trichomonas vaginalis* (17.4%) and *Chlamydia trachomatis* (21.9%) was significantly higher among women <24 years.⁵ Young pregnant women in other low-income or middle-income countries are similarly affected by STIs. Using a point-of-care testing strategy in a high-burden low-income setting in Papua New Guinea, women <24 years were more than twice (OR 2.38; 95% CI 1.09 to 5.21) likely to test positive for any STI in pregnancy.⁶ Almost half of adolescent pregnant women in a cross-sectional community survey in Tanzania tested positive for at least one STI, and herpes simplex virus-2 (HSV-2) was most commonly detected.⁷ The recent South African antenatal HIV-1 survey also highlighted the high HSV-2 seroprevalence among HIV-1 seropositive pregnant women.⁸

Any or a combination of the above STIs during pregnancy in virtue of its aetiology, pathogenesis and its proximity to the fetal–placental barrier could contribute to unfavourable pregnancy outcomes. Untreated HIV-1 infection, particularly among women who have not sought antenatal care, is significantly associated with stillbirths (RR 3.3), preterm births (RR 1.5), small for gestational age (RR 1.3) and low birthweight (RR 1.62) babies.⁹ Curable STIs in pregnancy, particularly if undiagnosed and untreated, have also been implicated in adverse pregnancy outcomes. *C. trachomatis* and *N. gonorrhoeae* in particular are commonly associated with premature rupture of membranes, preterm deliveries, fetal demise and low birth weight.^{10–13} Studies reporting genital shedding of HSV-2 in pregnancy are limited and provide little insight on the impact thereof on pregnancy outcomes.^{14–17}

We previously reported on the incidence and prevalence of three curable STIs in relation to HIV-1 in a cohort of pregnant women and remarked on the large proportion of asymptomatic STIs that would go undiagnosed when syndromic management is implemented.⁵ In this current analysis, we report on the prevalence of genital HSV-2 shedding in the same cohort of pregnant women and further explore the effect of genital shedding of HSV-2 and the previously reported STIs in association with treatment on pregnancy outcomes.



CrossMark

To cite: Moodley D, Sartorius B, Madurai S, et al. *Sex Transm Infect* 2017;**93**:460–466.

METHODS

Definitions of pregnancy outcomes

Births occurring <37 weeks gestation were defined as preterm. Gestational age was determined by obstetric measurements and in the absence of an ultrasound done within 24 weeks, an average measure by symphysis fundal height, last menstrual date and palpation was used to estimate gestational age at the first antenatal visit. Low birth weight was defined as <2500 g in term deliveries ≥37 weeks gestation and stillbirths were defined as fetal demise ≥21 weeks gestational age. A miscarriage was defined as fetal demise <21 weeks.

Study design

This is a secondary analysis of the South African HIV Antenatal Post-test Support Study (SAHAPS) study cohort, a behavioural intervention randomised control trial, that was conducted at a public health clinic in Umlazi, a periurban residential township in South Africa between May 2008 and June 2010.¹⁸ Pregnant women registering at the antenatal clinic were enrolled if they were 18 years or older, had not previously tested for HIV-1, were in a sexual relationship for the past 6 months and planned to reside in the area until the end of the study. Women who provided informed consent were interviewed and subsequently randomised to one of two arms to receive enhanced counselling sessions (intervention) or receive the standard counselling session (control). All enrolled participants received the standard prescribed antenatal care, had a genital swab taken to test for STIs and had a HIV-1 rapid test done. Details of the HIV-1 testing procedure are described in the primary manuscript.¹⁸ While participants continued with antenatal care at subsequent visits, participants who tested HIV-1 negative at the first visit also had a repeat HIV-1 test performed after 34 weeks gestation. Subsequent study visits were scheduled for 6, 10, 14 weeks and 9 months after delivery. Our retention strategy included a maximum of three telephonic contacts in the event of participants missing their study visits, and a home visit if participants fail to return to the clinic after telephonic reminders. Pregnancy outcomes were documented at the 6-week or 10-week postpartum visit. A genital swab was repeated at the 14-week postpartum visit. Genital swabs taken from pregnant women at their first antenatal visit and postpartum visit were tested for the curable STIs (*N. gonorrhoeae*, *C. trachomatis* and *T. vaginalis*) by PCR in real time and remaining genital specimens were processed and stored at -70°C.

In the parent study, a randomised controlled trial, 1480 pregnant women were randomised to an intervention arm or a control arm and expected to return for follow-up visits. Data for 1183 women were analysed at the 14-week postpartum visit. In summary, the counselling intervention had no effect on the incidence of STIs at the 14-week postpartum visit.

In this retrospective observational study, we conducted a sub-analysis of data for 615 pregnant women who were enrolled in the parent study and for whom we had adequate volumes of stored crude extracts of DNA from the genital specimens with an overall aim to determine the prevalence of HSV-2 shedding in the genital tract and evaluate the pregnancy outcomes in association with HSV-2 shedding and other STIs detected during pregnancy.

Detection of *N. gonorrhoeae*, *C. trachomatis* and *T. vaginalis*

As described in our previous report, the swabs were processed for the detection of *N. gonorrhoeae*, *C. trachomatis* and *T.*

vaginalis using the BD Probetec ET Amplified DNA Assay (Becton Dickinson, Maryland, USA) and Strand Displacement technology.⁵

Detection of HSV-1/2

Crude extracts of DNA remaining after PCR testing for *N. gonorrhoeae*, *C. trachomatis* and *T. vaginalis* were stored at -70°C. These DNA extracts were recently tested for HSV-1/2 DNA using the Light Cycler HSV1/2 Detection Kit Light Mix Kit (Roche Diagnostics, USA). The Kit is a real-time PCR assay that has been designed and adapted for use on The Light Cycler Roche Instrument.

Treatment for *C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis*

In compliance with the local syndromic management protocol, women reporting or presenting with vaginal discharge syndrome suggestive of an STD were initiated on treatment on the same day. The results from the laboratory diagnosis were available between 2 and 3 weeks and women who were asymptomatic but tested positive by laboratory diagnosis were contacted telephonically to inform them of their results and asked to return to the clinic at their earliest convenience or reminded of their next scheduled antenatal visit for initiation of treatment. Study nurses continued to provide antenatal care to all participants until delivery; in this way, participants with asymptomatic STIs would be initiated on treatment at their next routine clinic visit if they had not returned earlier.

Treatment for HIV-1

Between 2008 and 2010, pregnant women who tested positive for HIV-1 at their first antenatal visit were initiated on Zidovudine prophylaxis from 28 weeks of gestation for prevention of mother-to-child transmission of HIV-1 and subsequently commenced on a triple antiretroviral regimen when their CD4 count was available and met the criteria for treatment (CD4 < 200 cells/mL).

Statistical analysis

Data were analysed using Stata V.13.0 (StataCorp. 2013. Stata Statistical Software: Release V.13. College Station, TX: StataCorp LP). The difference in mean of continuous explanatory variables by adverse birth outcome was assessed using the Student's t-test. If a given explanatory variable were not normal, then the Wilcoxon rank-sum (Mann-Whitney U) test was used instead. The association between adverse birth outcome and categorised explanatory risk factors was assessed using a Pearson χ^2 test. If any cell count in the cross tabulation contained fewer than five expected observations, then the Fisher's exact test was used instead. Bivariate and multivariable adjusted logistic regression models were developed to assess the association of explanatory variables for adverse birth outcomes in the presence of other potential confounders/risk factors.

All the multivariable models were built using backwards elimination based on the likelihood ratio test to discriminate between variables that needed to be retained or if they could be removed without significantly altering the model fit. Variables in the final multivariable models were checked for collinearity using variance inflation factors. An adjusted p value of <0.05 was considered statistically significant.

A written informed consent was obtained from all women who participated in the main study.

RESULTS

Data for a total number of 615 pregnant women were included in this subanalysis, 36 (5.8%) of whom did not return after delivery and for whom we do not have birth outcomes. The average age of women in this subanalysis was 25.4 years, 49.4% were in the 18–24-year age group. Two hundred and ninety-four (47.9%) achieved only primary education and only 24.7% were living with their partner. Women in the subcohort had an average number of two pregnancies (36.8%) and 38.4% were first-time pregnancies. The median gestational age at antenatal registration was 24 weeks (IQR 20–27).

With a HIV-1 seroprevalence of 36.6%, 342 HIV-1 seronegative women were retested for HIV-1 prior to delivery. There were five HIV-1 seroconversions over a cumulative period of 157.37 years, HIV-1 incidence in pregnancy being 3.18 per 100 woman-years (95% CI 1.0 to 7.4). Four of the five women were in the 18–24-year age group.

One-third of pregnant women in this substudy cohort (33.4%; 95% CI 29.7 to 37.3) tested positive for any STIs and *C. trachomatis* and *T. vaginalis* were the most common pathogens; 17.8% and 15.3%, respectively. *N. gonorrhoeae* was detected in 6.4% (95% CI 4.6 to 8.7) of the women. Fifty-one (8.30%) women presented with more than one STI. Among the 203 women with any STI, only 87 (42.9%) women were symptomatic at the time of testing and at an average gestational age of 24 weeks. More than half (n=116 57.1%) were asymptomatic and did not receive treatment on the same day. The average gestational age at which these women tested positive for an STI was 24 weeks and the next clinic visit was scheduled for 32 weeks. Treatment records

were available for 158 (77.8%) women with any STI, all 87 women with symptomatic STIs were treated the same day and 50 (70.4%) among 71 asymptomatic women received treatment at the subsequent antenatal visit. Twenty-one (29.6%) of the asymptomatic women with an STI did not receive treatment. Reasons for women not receiving treatment were referrals to a regional hospital or women did not return for antenatal visits.

Genital HSV-2 shedding was prevalent in 51 of 615 (8.3%; 95% CI 6.3 to 10.8) women at the first antenatal visit. In a multivariable analysis adjusted for socioeconomic status, gravidity, *C. trachomatis*, *T. vaginalis* and *N. gonorrhoeae*, HIV-1 positive women were 2.5 times more likely to test positive for HSV-2 shedding (OR 2.5; 95% CI 1.44 to 4.35) (table 1). HSV-2 shedding was also significantly more common among 18–24-year age group (p=0.021). Only one of the five (20%) incident cases of HIV-1 was positive for genital HSV-2 shedding. Of the women who tested positive for HSV-2 genital shedding, six (11.8%) reported genital ulcers once before and 27.5% reported an abnormal vaginal discharge in the past year.

Only 20 (39.2%) women who tested positive for HSV-2 shedding at antenatal registration were symptomatic at the time of genital shedding. History of genital ulcers was not significantly associated with HSV-2 genital shedding (p=0.24). The median gestational age at which women tested positive for genital HSV-2 shedding was 25.3 weeks (IQR 19.3–28.7).

The pregnancy outcomes for 579 women were well documented; there were 542 live births with a median birth weight of 3.2 kg (IQR 2.9–3.5) and 47 (8.64%; 95% CI 6.5 to 11.4) were of low birth weight (<2500 g). One hundred (18.15%; 95% CI

Table 1 Determinants of HSV-2 shedding in genital tract of pregnant women in South Africa, 2010 (n=615)

Variable	HSV-2 (baseline)		Unadjusted p Value	Multivariable adjusted*	
	Negative (n=552)	Positive (n=63)		OR (95% CI)	p Value
Age group: n (row %)					
18–24	293 (88.0)	40 (12.0)	0.28	1 (ref.)	
25–34	219 (91.6)	20 (8.4)		0.47 (0.25 to 0.91)	0.02
35+	40 (93.0)	3 (7.0)		0.29 (0.07 to 1.24)	0.09
Socioeconomic status: n (row %)					
Low	196 (87.5)	28 (12.5)	0.34	1 (ref.)	
Medium	235 (92.2)	20 (7.8)		0.63 (0.36 to 1.12)	0.12
High	107 (88.4)	14 (11.6)		0.98 (0.48 to 1.98)	0.95
Unknown	14 (93.3)	1 (6.7)		0.48 (0.06 to 3.99)	0.50
HIV-1: n (row %)					
Negative	357 (92.7)	28 (7.3)	0.00	1 (ref.)	
Positive	195 (84.8)	35 (15.2)		2.46 (1.43 to 4.21)	0.00
<i>Neisseria gonorrhoeae</i> , n (row %)					
Negative	511 (89.8)	58 (10.2)	0.60	1 (ref.)	
Positive	34 (87.2)	5 (12.8)		1.02 (0.37 to 2.81)	0.97
<i>Trichomonas vaginalis</i> , n (row %)					
Negative	464 (89.7)	53 (10.3)	0.83	1 (ref.)	
Positive	81 (89.0)	10 (11.0)		0.93 (0.44 to 1.96)	0.85
<i>Chlamydia trachomatis</i> , n (row %)					
Negative	443 (89.7)	51 (10.3)	0.97	1 (ref.)	
Positive	103 (89.6)	12 (10.4)		0.92 (0.46 to 1.84)	0.81
Gravidity: median (IQR)	2 (1–2)	2 (1–3)	0.62	1.26 (0.95 to 1.66)	0.11
Clinical: n (%)					
Asymptomatic	363 (90.3)	39 (9.7)	0.53	1 (ref.)	
Symptomatic	188 (88.7)	24 (11.3)		0.99 (0.57 to 1.74)	0.98

*Adjusted for socioeconomic status, gravidity, chlamydia, trichomonas and gonorrhoea. HSV-2, herpes simplex virus-2.

15.1 to 21.7) women delivered preterm (<37 weeks). Ten women (1.7%; 95% CI 0.9 to 3.3) aborted spontaneously (<21 weeks) and 13 (2.25%; 95% CI 1.3 to 3.9) pregnancies ended in stillbirths \geq 21 weeks of gestation. There were 14 (2.4%; 95% CI 1.4 to 4.1) neonatal deaths.

The stillbirth rates were higher but not significantly higher among HSV-2 shedders (17.5% vs 12%), 18–24-year-old women (13.8% vs 10.9%), HIV-1 positive women (14.8% vs 11.2%), women positive for *N. gonorrhoeae* (23.1% vs 12%) and positive for *T. vaginalis* (17.6% vs 11.6%). In an unadjusted analysis, women infected with *N. gonorrhoeae* were 2.2 times more likely to have had their pregnancy ending in a stillbirth ($p < 0.05$) and this association was marginally significant in a multivariable logistic regression model using backwards elimination of variables in the model (table 2).

Genital HSV-2 shedding, HIV-1, *N. gonorrhoeae*, *C. trachomatis* and *T. vaginalis* were also not associated with increased risk for preterm deliveries (table 3) and low birth weight (table 4). However, asymptomatic women with untreated curable STIs were 3.3 times more likely to deliver prematurely ($p = 0.048$) when compared with women who received treatment during pregnancy (table 4). A comparison of pregnancy outcomes among women who received syndromic treatment on the day of diagnosis and

women who initiated treatment at the subsequent antenatal visit yielded no difference in the proportion of stillbirths, preterm deliveries and low birthweight babies.

The proportion of live births was not significantly lower among women with multiple STIs (95.74%) when compared with women with no STIs (94.21%) and women with a single STI (91.67%) ($p = 0.308$). Likewise, the proportion of low birth weight (LBW) and preterm birth (PTB) babies born to women with coinfections (6.67%, 18.18%) were not significantly higher than women with a single STI (8.50%, 17.42%) and no STI (8.99%, 18.23%) ($p = 0.476$, $p = 0.486$).

DISCUSSION

In this secondary analysis of a cohort study of young women in a periurban community with an antenatal HIV-1 seroprevalence of 36.6%, we report genital HSV-2 shedding in 8.3% of the women during pregnancy. HIV-1 positive pregnant women in our study were twice more likely to be diagnosed with genital HSV-2 shedding. HSV-2 shedding in pregnancy, after adjusting for HIV-1, *T. vaginalis*, *C. trachomatis* or *N. gonorrhoeae*, and demographic characteristics were not associated with the occurrence of stillbirths, preterm births and low birthweight babies. However, untreated curable STIs are more likely associated with preterm births.

Table 2 HSV-2 shedding and modifiers that influence live births in South Africa, 2010 (n=615)

Variable	Birth outcome		Unadjusted OR (95% CI) for adverse outcome	p Value	Multivariable adjusted*	
	Live born (N=538, 87.5%)	Not live born (N=77, 12.5%)			OR (95% CI) for adverse outcome	p Value
HSV-2 shedding: n (%)						
No	486 (88)	66 (12)	1 (ref.)		1 (ref.)	
Yes	52 (82.5)	11 (17.5)	1.6 (0.8 to 3.1)	0.21	1.3 (0.7 to 2.8)	0.42
Age group: n (%)						
18–24	287 (86.2)	46 (13.8)	1 (ref.)		1 (ref.)	
25–34	213 (89.1)	26 (10.9)	0.8 (0.5 to 1.3)	0.30	0.6 (0.3 to 1.1)	0.12
35–44	38 (88.4)	5 (11.6)	0.8 (0.3 to 2.2)	0.69	0.5 (0.1 to 1.6)	0.22
HIV-1: n (%)						
No	342 (88.8)	43 (11.2)	1 (ref.)		1 (ref.)	
Yes	196 (85.2)	34 (14.8)	1.4 (0.9 to 2.2)	0.19	1.3 (0.8 to 2.1)	0.39
Gravidity: median (IQR)	2 (1–2)	2 (1–3)	1.1 (0.9 to 1.3)	0.55	1.2 (0.9 to 1.6)	0.14
Socioeconomic status: n (%)						
Unknown	13 (86.7)	2 (13.3)	0.9 (0.2 to 4.1)	0.88	0.9 (0.2 to 4.5)	0.92
Low	191 (85.3)	33 (14.7)	1 (ref.)		1 (ref.)	
Medium	229 (89.8)	26 (10.2)	0.7 (0.4 to 1.1)	0.13	0.7 (0.4 to 1.3)	0.26
High	105 (86.8)	16 (13.2)	0.9 (0.5 to 1.7)	0.70	1 (0.5 to 1.9)	0.99
<i>Neisseria gonorrhoeae</i> , n (%)†						
No	501 (88.0)	68 (12.0)	1 (ref.)		1 (ref.)	
Yes	30 (76.9)	9 (23.1)	2.2 (1 to 4.9)	0.05	2.2 (1.0 to 4.9)	0.05
<i>Trichomonas vaginalis</i> , n (%)†						
No	457 (88.4)	60 (11.6)	1 (ref.)		1 (ref.)	
Yes	75 (82.4)	16 (17.6)	1.6 (0.9 to 3)	0.12	1.6 (0.9 to 3)	0.13
<i>Chlamydia trachomatis</i> , n (%)‡						
No	429 (86.8)	65 (13.2)	1 (ref.)		1 (ref.)	
Yes	103 (89.6)	12 (10.4)	0.8 (0.4 to 1.5)	0.43	0.7 (0.4 to 1.4)	0.28
Treated for STIs						
No	17 (94.5)	1 (5.5)	1 (ref.)			
Yes	108 (93.9)	7 (6.1)	0.91 (0.11 to 7.74)	0.69	–	–
Same day	36 (94.7)	2 (5.3)	1 (ref.)			
Subsequent visit	72 (93.5)	5 (6.5)	1.25 (0.23 to 6.76)	0.58		

*Adjusted for age, gravidity, socioeconomic status, HIV-1, chlamydia, trichomonas and gonorrhoea.

†Seven subjects with unknown or missing results.

‡Six subjects with unknown or missing data.

HSV-2, herpes simplex virus-2.

Table 3 HSV-2 shedding and modifiers that may influence preterm deliveries in South Africa, 2010 (n=574)*

Variable	Birth outcome		OR (95% CI) for adverse outcome	p Value	Multivariable adjusted†	
	Term (N=415, 72.3%)	Preterm (N=159, 27.7%)			OR (95% CI) for adverse outcome	p Value
HSV-2 shedding: n (%)						
No	372 (72.1)	144 (27.9)	1 (ref.)		1 (ref.)	
Yes	43 (74.1)	15 (25.9)	0.9 (0.5 to 1.7)	0.74	0.9 (0.5 to 1.7)	0.68
Age group: n (%)						
18–24	216 (70.8)	89 (29.2)	1 (ref.)		1 (ref.)	
25–34	162 (71.7)	64 (28.3)	1 (0.7 to 1.4)	0.83	0.9 (0.6 to 1.3)	0.64
35–44	37 (86.0)	6 (14.0)	0.4 (0.2 to 1)	0.04	0.4 (0.2 to 0.9)	0.04
HIV-1: n (%)						
No	263 (73.1)	97 (26.9)	1 (ref.)		1 (ref.)	
Yes	152 (71.0)	62 (29.0)	1.1 (0.8 to 1.6)	0.6	1.1 (0.7 to 1.6)	0.69
Gravidity: median (IQR)	2 (1–2)	2 (1–2)	0.9 (0.8 to 1.1)	0.34	1 (0.8 to 1.2)	0.93
Socioeconomic status: n (%)						
Unknown	11 (78.6)	3 (21.4)	0.9 (0.2 to 4.1)	0.88	0.8 (0.2 to 3.2)	0.76
Low	150 (73.2)	55 (26.8)	1 (ref.)		1 (ref.)	
Medium	166 (68.3)	77 (31.7)	0.7 (0.4 to 1.1)	0.13	1.3 (0.8 to 1.9)	0.27
High	88 (78.6)	24 (21.4)	0.9 (0.5 to 1.7)	0.70	0.7 (0.4 to 1.3)	0.31
<i>Neisseria gonorrhoeae</i> , n (%)‡						
No	390 (73.0)	144 (27.0)	1 (ref.)		1 (ref.)	
Yes	21 (61.8)	13 (38.2)	1.7 (0.8 to 3.4)	0.16	1.7 (0.8 to 3.5)	0.17
<i>Trichomonas vaginalis</i> , n (%)§						
No	354 (72.7)	133 (27.3)	1 (ref.)		1 (ref.)	
Yes	58 (70.7)	24 (29.3)	1.1 (0.7 to 1.8)	0.71	1.1 (0.7 to 1.9)	0.67
<i>Chlamydia trachomatis</i> , n (%)§						
No	334 (72)	130 (28)	1 (ref.)		1 (ref.)	
Yes	78 (74.3)	27 (25.7)	0.9 (0.5 to 1.4)	0.63	0.8 (0.5 to 1.2)	0.27
Treated for STIs						
No	12 (66.7)	6 (33.3)	1 (ref.)			
Yes	99 (86.8)	15 (13.2)	3.3 (1.08 to 10.12)	0.041†	–	–
Same day	68 (88.3)	9 (11.7)	1 (ref.)			
Subsequent visit	31 (83.8)	6 (16.2)	1.46 (0.48 to 4.47)	0.346		

*36 women who were lost to follow-up, 77 pregnancies ending in stillbirths and 5 women for whom pregnancy outcomes were not available were excluded from this analysis.

†Adjusted for age, gravidity, socioeconomic status, HIV-1, chlamydia, trichomonas and gonorrhoea.

‡Six Subjects with unknown or missing status.

§Five subjects with unknown or missing results.

HSV-2, herpes simplex virus-2.

The South African antenatal survey in 2012 underscored the high HSV-2 seroprevalence in the antenatal population and particularly the strong correlation between HIV-1 and HSV-2 seroprevalence.⁸ Similar to the findings of the antenatal survey, HIV-1 positive pregnant women in our study were twice more likely to be diagnosed with HSV-2 shedding. However, unlike HSV-2 seroprevalence which is known to increase with age, genital HSV-2 shedding was significantly more common among the younger women in our study. Studies have reported higher HSV-2 incidence among younger women (18–24 years), and increased genital shedding is characteristically related to incident HSV-2 infections. The absence of serological testing in our study is a major limitation to confirming whether the younger women presented with incident HSV-2 infections.

Our finding of genital shedding in 15% of HIV-1 positive women in pregnancy has implications for preventing a recurrence in shedding around the time of labour. In recent studies of South African women in labour, genital shedding of HSV-2 was significantly more common among HIV-1 positive women (17.2–30.8%) versus HIV-1 negative women (9.5–11.8%) and more than 90% of these women were asymptomatic.^{16 17} The

authors concluded that reactivation of HSV-2 is more likely to occur among HIV-1 positive women in labour and certainly has implications for screening and treatment of neonatal herpes. In a Cochrane systematic review, Holier and Wendel concluded that antiviral prophylaxis for HSV-2 in women in pregnancy reduces the risk of a recurrence in genital shedding and the risk of neonatal infection.¹⁹ Further studies are needed to determine the cost-effectiveness of treating all HSV-2 seropositive pregnant women or targeted treatment of HIV-1/HSV-2 coinfecting pregnant women.

Our findings of similar pregnancy outcomes among HIV-1 infected and uninfected women are not surprising since all HIV-1 positive pregnant women in this randomised control study received antiretroviral prophylaxis for prevention of mother to child transmission (PMTCT) or subsequently initiated antiretroviral treatment if eligible. In a multivariable regression analysis adjusting for demographic characteristics and antiretroviral use in pregnant women from the same catchment population as our study, HIV-1 infection in the absence of antiretroviral treatment remained strongly associated with an increased odds of preterm delivery, stillbirths, low birth weight

Table 4 HSV-2 shedding and modifiers that may influence birth weight in South Africa, 2010 (n=557)*

Variable	Birth outcome		OR (95% CI) for adverse outcome	p Value	Multivariable adjusted†	
	Normal birth weight (N=502, 90.1%)	Low birth weight (N=55, 9.9%)			OR (95% CI) for adverse outcome	p Value
HSV-2 shedding: n (%)						
No	454 (90.6)	47 (9.4)	1 (ref.)		1 (ref.)	
Yes	48 (85.7)	8 (14.3)	1.6 (0.7 to 3.6)	0.25	1.4 (0.6 to 3.2)	0.46
Age group: n (%)						
18–24	269 (90.3)	29 (9.7)	1 (ref.)		1 (ref.)	
25–34	196 (89.5)	23 (10.5)	1.1 (0.6 to 1.9)	0.77	1.1 (0.5 to 2.1)	0.87
35–44	37 (92.5)	3 (7.5)	0.8 (0.2 to 2.6)	0.65	0.8 (0.2 to 3.3)	0.75
HIV-1: n (%)						
No	328 (91.9)	29 (8.1)	1 (ref.)		1 (ref.)	
Yes	174 (87.0)	26 (13.0)	1.7 (1 to 3)	0.07	1.7 (0.9 to 3.1)	0.05
Gravidity: median (IQR)	2 (1–2)	2 (1–2)	0.9 (0.7 to 1.2)	0.47	0.9 (0.6 to 1.2)	0.44
Socioeconomic status: n (%)						
Unknown	13 (92.9)	1 (7.1)	0.5 (0.1 to 4.1)	0.53	0.6 (0.1 to 5)	0.63
Low	168 (87.0)	25 (13.0)	1 (ref.)		1 (ref.)	
Medium	218 (91.2)	21 (8.8)	0.6 (0.4 to 1.2)	0.17	0.7 (0.4 to 1.2)	0.19
High	103 (92.8)	8 (7.2)	0.5 (0.2 to 1.2)	0.13	0.5 (0.2 to 1.1)	0.09
<i>Neisseria. gonorrhoeae</i> , n (%)‡						
No	467 (90.2)	51 (9.8)	1 (ref.)		1 (ref.)	
Yes	29 (90.6)	3 (9.4)	0.9 (0.3 to 3.2)	0.93	0.9 (0.2 to 3.1)	0.84
<i>Trichomonas vaginalis</i> , n (%)§						
No	428 (90.7)	44 (9.3)	1 (ref.)		1 (ref.)	
Yes	69 (87.3)	10 (12.7)	1.4 (0.7 to 2.9)	0.36	1.3 (0.6 to 2.8)	0.49
<i>Chlamydia trachomatis</i> , n (%)§						
No	398 (89.6)	46 (10.4)	1 (ref.)		1 (ref.)	
Yes	99 (92.5)	8 (7.5)	0.7 (0.3 to 1.5)	0.37	0.6 (0.3 to 1.4)	0.27
Treated for STIs						
No	17 (94.5)	1 (5.5)	1 (ref.)			
Yes	106 (93.8)	7 (6.2)	0.89 (0.10 to 7.70)	0.698	–	–
Same day	72 (94.5)	5 (6.5)	1 (ref.)			
Subsequent visit	34 (94.4)	2 (5.6)	0.85 (0.11 to 4.53)	0.606		

*36 women who were lost to follow-up, 22 women for whom birth weights were not available were excluded from this analysis.

†Adjusted for age, gravidity, socioeconomic status, HIV-1, chlamydia, trichomonas and gonorrhoea.

‡Seven subjects with unknown or missing status.

§Six subjects with unknown or missing results.

HSV-2, herpes simplex virus-2.

and small for gestational age.⁹ A recent meta-analysis of 35 studies showed consistent evidence of a strong association between maternal HIV-1 infection and preterm birth, low birth weight, miscarriages and stillbirths, largely in Sub-Saharan Africa.²⁰ The *Lancet HIV* meta-analysis underscored the implications of not providing antiretroviral treatment to pregnant women.²⁰

All STIs in pregnancy by virtue of their close proximity to the placenta are plausible causes of premature rupture of membranes, preterm deliveries, fetal demise and low birth weight. Our findings of the lack of association between the curable STIs and adverse pregnancy outcomes are also supported by many other studies that demonstrated an improvement in pregnancy outcomes when early screening and treatment of STIs are included in the antenatal care package. The authors in these studies concluded that screening and treatment of *C. trachomatis* in the first trimester resulted in significantly lower rates of preterm births, particularly among adolescents, when compared with the reference group of women who had *C. trachomatis* detected later in pregnancy.²¹ Earlier studies in Uganda and India also found a reduction in low birth weight, preterm delivery, stillbirths and neonatal deaths in women with recognised

and treated STIs.^{22 23} The higher preterm birth rate among the asymptomatic women in our study who did not return for follow-up and therefore not receive treatment is additional evidence that STIs can cause adverse pregnancy outcomes if untreated.

It must be noted that pregnant women in our study who presented with a symptomatic genital tract infection received syndromic management on the same day, while women who were asymptomatic but had a laboratory diagnosis of any of the curable STIs also received appropriate treatment at their subsequent antenatal visit but before delivery. With the use of laboratory investigations in this randomised controlled behavioural intervention study, we were able to provide maximum treatment coverage for women with *N. gonorrhoeae*, *C. trachomatis* or *T. vaginalis* who were symptomatic or asymptomatic. Although, besides being costly and laboratory based, treatment is delayed until the next visit and there is no guarantee that all women will return for subsequent antenatal visits. Our findings have implications for re-examining antenatal care guidelines that only prescribe syndromic management in the detection and treatment of STIs. More recent studies evaluating point-of-care tests for early detection of STIs and exploring the acceptability and feasibility

Clinical

of on-site testing strategies for pregnant women are encouraging.^{6 24–26} Early detection and treatment of curable STIs have an impact on pregnancy outcomes and could avert incident HIV-1 infections during pregnancy.²⁷

Our study has several limitations. The primary study excluded women who registered late for antenatal care and are therefore excluded from our analysis. Our findings are therefore only relevant to women who seek antenatal care before 34 weeks in pregnancy. Other curable STIs that could have also contributed to adverse pregnancy outcomes such as syphilis and bacterial vaginosis were omitted in the data collection. We did not include these tests in the primary study, although women were routinely screened for syphilis.

In conclusion, genital HSV-2 shedding in pregnancy does not appear to alter pregnancy outcomes; however, untreated curable STIs (*T. vaginalis*, *C. trachomatis*, *N. gonorrhoeae*) in this study population were more likely associated with preterm births only. We believe point-of-care diagnostics and comprehensive management of these STIs in pregnancy could avert adverse pregnancy outcomes commonly associated with these STIs.

Key messages

- ▶ Genital shedding of herpes simplex virus-2 (HSV-2) is common among young HIV-1 infected women during pregnancy.
- ▶ Genital shedding of HSV-2 like the other common STIs *Trichomonas vaginalis*, *Chlamydia trachomatis* and *Neisseria gonorrhoeae* was largely asymptomatic during pregnancy.
- ▶ While symptomatic women are more likely to be treated the same day, close to one-third of women who are asymptomatic will not return for treatment.
- ▶ The occurrence of stillbirths (17.5%) and low birth weight (14.3%) were not significantly associated with HSV-2 shedding, HIV-1, *C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis*.
- ▶ Asymptomatic women with untreated curable STIs were 3.3 times more likely to deliver prematurely when compared with women who received treatment during pregnancy.
- ▶ Reliable affordable point-of-care testing of STIs is urgently needed at public health facilities to ensure that all women with curable STIs receive treatment early in pregnancy.

Handling editor Jackie A Cassell

Contributors DM conceptualised the substudy, interpreted the statistical analysis and wrote the manuscript. BS performed the statistical analysis and contributed to the development of the manuscript. SM and VC coordinated the laboratory tests, interpreted the data and reviewed the manuscript. Susanne Maman was the principal investigator of the primary study, conceptualised the substudy and helped write the manuscript.

Funding This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant number R01HD050134) and The Open Society Institute and Elton John Foundation (grant number 20020472/20030878).

Competing interests None declared.

Ethics approval The main study was approved by the institutional review boards of the University of KwaZulu-Natal (E129/06) and the University of North Carolina at Chapel Hill (07-1070) and the University of KwaZulu-Natal ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf (accessed 22 May 2016).
- 2 Naidoo S, Wand H, Abbai NS, *et al.* High prevalence and incidence of sexually transmitted infections among women living in KwaZulu-Natal, South Africa. *AIDS Res Ther* 2014;11:31.
- 3 Jonas K, Crutzen R, van den Borne B, *et al.* Teenage pregnancy rates and associations with other health risk behaviours: a three-wave cross-sectional study among South African school-going adolescents. *Reprod Health* 2016;13:50.
- 4 Althabe F, Moore JL, Gibbons L, *et al.* Adverse maternal and perinatal outcomes in adolescent pregnancies: the Global Network's Maternal Newborn Health Registry study. *Reprod Health* 2015;12(Suppl 2):S8.
- 5 Moodley D, Moodley P, Sebitloane M, *et al.* High prevalence and incidence of asymptomatic sexually transmitted infections during pregnancy and postdelivery in KwaZulu Natal, South Africa. *Sex Transm Dis* 2015;42:43–7.
- 6 Badman SG, Valley LM, Toliman P, *et al.* A novel point-of-care testing strategy for sexually transmitted infections among pregnant women in high-burden settings: results of a feasibility study in Papua New Guinea. *BMC Infect Dis* 2016;16:250.
- 7 Hikororo A, Kihunrwa A, Hoekstra P, *et al.* High prevalence of sexually transmitted infections in pregnant adolescent girls in Tanzania: a multi-community cross-sectional study. *Sex Transm Infect* 2015;91:473–8.
- 8 South African Department of Health. *The 2012 National Antenatal Sentinel HIV and Herpes Simplex type-2 prevalence survey*. South Africa: National Department of Health, 2013.
- 9 Moodley T, Moodley D, Sebitloane M, *et al.* Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. *BMC Pregnancy Childbirth* 2016;16:35.
- 10 Adachi K, Klausner JD, Xu J, *et al.*, NICHD HPTN 040 Study Team. *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in HIV-infected pregnant women and adverse infant outcomes. *Pediatr Infect Dis J* 35:894–900.
- 11 Ahmadi A, Khodabandehloo M, Ramazanzadeh R, *et al.* The relationship between *Chlamydia trachomatis* genital infection and spontaneous abortion. *J Reprod Infertil* 2016;17:110–16.
- 12 Blas MM, Canchihuaman FA, Alva IE, *et al.* Pregnancy outcomes in women infected with *Chlamydia trachomatis*: a population-based cohort study in Washington State. *Sex Transm Infect* 2007;83:314–18.
- 13 Adachi K, Nielsen-Saines K, Klausner JD. *Chlamydia trachomatis* infection in pregnancy: the Global Challenge of Preventing Adverse Pregnancy and Infant Outcomes in Sub-Saharan Africa and Asia. *Biomed Res Int* 2016;2016:9315757.
- 14 Li DK, Raebel MA, Cheetham TC, *et al.* Genital herpes and its treatment in relation to preterm delivery. *Am J Epidemiol* 2014;180:1109–17.
- 15 Bujko M, Sulovic V, Zivanovic V, *et al.* Herpes simplex virus infection in women with previous spontaneous abortion. *J Perinat Med* 1988;16:193–6.
- 16 Perti T, Nyati M, Gray G, *et al.* Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. *Infect Dis Obstet Gynecol* 2014;2014:258291.
- 17 Patterson J, Hitti J, Selke S, *et al.* Genital HSV detection among HIV-1-infected pregnant women in labor. *Infect Dis Obstet Gynecol* 2011;2011:157680.
- 18 Maman S, Moodley D, McNaughton-Reyes HL, *et al.* Efficacy of enhanced HIV counseling for risk reduction during pregnancy and in the postpartum period: a randomized controlled trial. *PLoS ONE* 2014;9:e97092.
- 19 Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. *Cochrane Database Syst Rev* 2008;(1):CD004946.
- 20 Wedi CO, Kirtley S, Hopewell S, *et al.* Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. *Lancet HIV* 2016;3:e33–48.
- 21 Folger AT. Maternal *Chlamydia trachomatis* infections and preterm birth: the impact of early detection and eradication during pregnancy. *Matern Child Health J* 2014;18:1795–802.
- 22 Rastogi S, Das B, Salhan S, *et al.* Effect of treatment for *Chlamydia trachomatis* during pregnancy. *Int J Gynaecol Obstet* 2003;80:129–37.
- 23 Gray RH, Wabwire-Mangen F, Kigozi G, *et al.* Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. *Am J Obstet Gynecol* 2001;185:1209–17.
- 24 Hill MG, Menon S, Smith S, *et al.* Screening for Chlamydia and Gonorrhea Cervicitis and implications for pregnancy outcome. Are we testing and treating at the right time? *J Reprod Med* 2015;60:301–8.
- 25 Wynn A, Ramogola-Masire D, Gaolebale P, *et al.* Acceptability and feasibility of sexually transmitted infection testing and treatment among pregnant women in Gaborone, Botswana, 2015. *Biomed Res Int* 2016;2016:1251238.
- 26 Brook G. The performance of non-NAAT point-of-care (POC) tests and rapid NAAT tests for chlamydia and gonorrhoea infections. An assessment of currently available assays. *Sex Transm Infect* 2015;91:539–44.
- 27 Kinuthia J, Drake AL, Matemo D, *et al.* HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. *AIDS* 2015;29:2025–33.



Pregnancy Outcomes in Association with STDs including genital HSV-2 shedding in a South African Cohort Study

Dhayendre Moodley, Benn Sartorius, Savithree Madurai, Vani Chetty and Suzanne Maman

Sex Transm Infect 2017 93: 460-466 originally published online April 10, 2017

doi: 10.1136/sextrans-2017-053113

Updated information and services can be found at:
<http://sti.bmj.com/content/93/7/460>

These include:

References

This article cites 23 articles, 3 of which you can access for free at:
<http://sti.bmj.com/content/93/7/460#BIBL>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Editor's choice](#) (83)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>